# A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects

> **NCT05031624** · PHASE1 · COMPLETED · sponsor: **Celldex Therapeutics** · enrollment: 32 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** CDX-0159
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT05031624
- **Lead sponsor:** Celldex Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-30
- **Primary completion:** 2022-01-14
- **Final completion:** 2022-01-14
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05031624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05031624, "A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05031624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*